Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease

American Journal of Respiratory Cell and Molecular Biology

Volumn 44, Issue 3, 2011, Pages 316-322

  Foreman, Marilyn G ^a,c   Kong, Xiangyang ^b   DeMeo, Dawn L ^c   Pillai, Sreekumar G ^b   Hersh, Craig P ^c   Bakke, Per ^d,e   Gulsvik, Amund ^d,e   Lomas, David A ^f   Litonjua, Augusto A ^c   Shapiro, Steven D ^g   Tal Singer, Ruth ^b   Silverman, Edwin K ^c  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

COPD; Genetics; Single nucleotide polymorphisms; Surfactant protein D

Indexed keywords

SURFACTANT PROTEIN D;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGING; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D;

EID: 79952228818     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0360OC     Document Type: Article

References (54)

1. Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac Soc 2005;2:403-411. (Pubitemid 43128033)
2. Alcorn JF, Wright JR. Degradation of pulmonary surfactant protein D by Pseudomonas aeruginosa elastase abrogates innate immune function. J Biol Chem 2004;279:30871-30879. (Pubitemid 38938023)
3. Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol 2005;42:279-287. (Pubitemid 39626759)
4. Nadesalingam J, Reid KB, Palaniyar N. Collectin surfactant protein D binds antibodies and interlinks innate and adaptive immune systems. FEBS Lett 2005;579:4449-4453. (Pubitemid 41116380)
5. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 2002;169:3978-3986.
6. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 2006;174:886-893. (Pubitemid 44564788)
7. Park JW, Ryter SW, Choi AM. Functional significance of apoptosis in chronic obstructive pulmonary disease. COPD 2007;4:347-353. (Pubitemid 350135869)
8. Guo CJ, Atochina-Vasserman EN, Abramova E, Foley JP, Zaman AM, Crouch E, Beers MF, Savani RC, Gow AJ. S-nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol 2008;6:e266.
9. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;34:95-102.
10. Leth-Larsen R, Garred P, Jensenius H, Meschi J, Hartshorn K, Madsen J, Tornoe I, Madsen HO, Sørensen G, Crouch E, Holmskov U. A common polymorphism in the SFTPD gene influences assembly, function, and concentration of surfactant protein D. J Immunol 2005;174:1532-1538.
11. National Emphysema Treatment Trial Research Group. Rationale and design of the National Emphysema Treatment Trial (NETT): a prospective randomized trial of lung volume reduction surgery. J Thorac Cardiovasc Surg 1999;118:518-528.
12. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001;345:1075-1083.
13. Litonjua AA, Lazarus R, Sparrow D, Demolles D, Weiss ST. Lung function in Type 2 diabetes: the Normative Aging Study. Respir Med 2005;99:1583-1590. (Pubitemid 41683939)
14. Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ, O'Donnell WJ, Reilly JJ, Ginns L, Mentzer S, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157:1770-1778.
15. Hersh CP, DeMeo DL, Al-Ansari E, Carey VJ, Reilly JJ, Ginns LC, Silverman EK. Predictors of survival in severe, early onset COPD. Chest 2004;126:1443-1451. (Pubitemid 39525015)
16. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE). Eur Respir J 2008;4:869-873.
17. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555. (Pubitemid 47403272)
18. Zhu G, Warren L, Aponte J, Gulsvik A, Bakke P, Anderson WH, Lomas DA, Silverman EK, Pillai SG; International COPD Genetics Network (ICGN) Investigators. The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med 2007;176:167-173. (Pubitemid 47057853)
19. Pillai SG, Gulsvik A, Lomas DA, Silverman EK. SERPINE2 and COPD. Am J Respir Crit Care Med 2007;176:726.
20. International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-1320.
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265. (Pubitemid 40202029)
22. Shi MM. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem 2001;47:164-172. (Pubitemid 32142913)
23. Paez JG, Lin M, Beroukhim R, Lee JC, Zhao X, Richter DJ, Gabriel S, Herman P, Sasaki H, Altshuler D, et al. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res 2004;32:e71.
24. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009;5:e1000421.
25. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995;152:1860-1866.
26. Inoue T, Matsuura E, Nagata A, Ogasawara Y, Hattori A, Kuroki Y, Fujimoto S, Akino T. Enzyme-linked immunosorbent assay for human pulmonary surfactant protein D. J Immunol Methods 1994;173:157-164. (Pubitemid 24259589)
27. Nagae H, Takahashi H, Kuroki Y, Honda Y, Nagata A, Ogasawara Y, Abe S, Akino T. Enzyme-linked immunosorbent assay using F(ab′)2 fragment for the detection of human pulmonary surfactant protein D in sera. Clin Chim Acta 1997;266:157-171. (Pubitemid 28034195)
28. Freidlin B, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered 2002;53:146-152.
29. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet 1998;63:259-266. (Pubitemid 30428342)
30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575. (Pubitemid 47330214)
31. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-909. (Pubitemid 44141658)
32. Wert SE, Yoshida M, LeVine AM, Ikegami M, Jones T, Ross GF, Fisher JH, Korfhagen TR, Whitsett JA. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci USA 2000;97:5972-5977. (Pubitemid 30367508)
33. Yoshida M, Korfhagen TR, Whitsett JA. Surfactant protein D regulates NF-kappa B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J Immunol 2001;166:7514-7519. (Pubitemid 32525630)
34. Senft AP, Korfhagen TR, Whitsett JA, Shapiro SD, LeVine AM. Surfactant protein-D regulates soluble CD14 through matrix metalloproteinase-12. J Immunol 2005;174:4953-4959. (Pubitemid 40514461)
35. Yoshida M, Whitsett JA. Alveolar macrophages and emphysema in surfactant protein-D-deficient mice. Respirology 2006;11:S37-S40.
36. Knudsen L, Ochs M, Mackay R, Knudsen L, Ochs M, Mackay R, Townsend P, Deb R, Mühlfeld C, Richter J, et al. Truncated recombinant human SP-D attenuates emphysema and Type II cell changes in SP-D deficient mice. Respir Res 2007;8:70.
37. Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc 2007;4:252-257. (Pubitemid 47036444)
38. Husby S, Herskind AM, Jensenius JC, Holmskov U. Heritability estimates for the constitutional levels of the collectins mannan-binding lectin and lung surfactant protein D: a study of unselected like-sexed mono- and dizygotic twins at the age of 6-9 years. Immunology 2002;106:389-394. (Pubitemid 34748133)
39. Heidinger K, Konig IR, Bohnert A, Kleinsteiber A, Hilgendorff A, Gortner L, Ziegler A, Chakraborty T, Bein G. Polymorphisms in the human surfactant protein-D (SFTPD) gene: strong evidence that serum levels of surfactant protein-D (SP-D) are genetically influenced. Immunogenetics 2005;57:1-7. (Pubitemid 40591241)
40. Sorensen GL, Hjelmborg JB, Kyvik KO, Fenger M, Høj A, Bendixen C, Sørensen TI, Holmskov U. Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol 2006;290:L1010-L1017. (Pubitemid 43725064)
41. Cao Y, Grous M, Scanlon S, Beers MF, Panettieri RA, Salmon M, Haczku A. The innate molecule surfactant protein (SP-D) is upregulated in the lung following cigarette smoke (CS) exposure in a murine model. Am J Respir Crit Care Med 2004;169:A832.
42. Kierstein S, Poulain FR, Cao Y, Grous M, Mathias R, Kierstein G, Beers MF, Salmon M, Panettieri RA Jr., Haczku A. Susceptibility to ozone-induced airway inflammation is associated with decreased levels of surfactant protein D. Respir Res 2006;7:85.
43. Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007;7:13.
44. Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1207-1214. (Pubitemid 351860929)
45. Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF, Panettieri RA, Haczku A. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008;9:13.
46. Dahl M. Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein. Am J Respir Crit Care Med 2008;177:1177-1178. (Pubitemid 351860923)
47. Sorensen GL, Hjelmborg JV, Leth-Larsen R, Schmidt V, Fenger M, Poulain F, Hawgood S, Sørensen TI, Kyvik KO, Holmskov U. Surfactant protein D of the innate immune defence is inversely associated with human obesity and SP-D deficiency infers increased body weight in mice. Scand J Immunol 2006;64:633-638. (Pubitemid 44704312)
48. Zhao XM, Wu YP, Wei R, Cai HX, Tornoe I, Han JJ, Wang Y, de Groot PG, Holmskov U, Xia ZL, Sorensen GL. Plasma surfactant protein D levels and the relation to body mass index in a Chinese population. Scand J Immunol 2007;66:71-76. (Pubitemid 46985509)
49. Guo X, Lin HM, Lin Z, Montaño M, Sansores R, Wang G, DiAngelo S, Pardo A, Selman M, Floros J. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J 2001;18:482-490. (Pubitemid 32895633)
50. van Diemen CC, Postma DS, Aulchenko YS, Snijders PJ, Oostra BA, van Duijn CM, Boezen HM. Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate. Eur Respir J 2010;35:768-775.
51. Hersh CP, Demeo DL, Lange C, Litonjua AA, Reilly JJ, Kwiatkowski D, Laird N, Sylvia JS, Sparrow D, Speizer FE, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 2005;33:71-78. (Pubitemid 40961016)
52. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, Barrett J, Engle M, Perret KA, Rubin BK. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997;278:1426-1431. (Pubitemid 27475971)
53. Hersh CP, Hansel NN, Barnes KC, Lomas DA, Pillai SG, Coxson HO, Mathias RA, Rafaels NM, Wise RA, Connett JE, et al. Transforming growth factor-beta receptor-3 is associated with pulmonary emphysema. Am J Respir Cell Mol Biol 2009;41:324-331.
54. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-664. (Pubitemid 11117589)